22 completed, 14 terminated, 11 recruiting, 8 active not recruiting. 51 Phase 2, 11 Phase 1, 7 Phase 3, 1 Not applicable.
Follow ponatinib: new trials by email Literature Review of ponatinib trials Research Report on ponatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma Cyclophosphamide, Doxorubicin, Etoposide - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 2 | Recruiting | University of Washington | 33 | 2026-03-30 | 2026-08-13 |
| A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia Randomization + Blinatumomab + chemotherapy, Randomization + Standard frontline T-ALL chemotherapy backbone, Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 1200 | 2025-05-06 | 2026-02-10 |
| Using Tumor Models to Determine Treatments Cobimetinib, Ponatinib, Brigatinib - Pancreatic Ductal Carcinoma, Advanced Cancer | Phase 2 | Recruiting | University Health Network, Toronto | 25 | 2025-04-07 | 2026-06-23 |
| A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) LP-118, Ponatinib, Vincristine - Acute Leukemia, Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | University of Chicago | 15 | 2024-09-13 | 2026-03-18 |
| The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP Ponatinib, Azacitidine, Venetoclax - Chronic Myeloid Leukemia | Recruiting | Peking University People's Hospital | 30 | 2024-07-01 | 2025-06-03 | |
| Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy - Acute Lymphoblastic Leukemia | Phase 2 | Withdrawn | University of Michigan Rogel Cancer Center | 2024-01-01 | 2024-02-22 | |
| Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL Vincristine, Dexamethasone, Imatinib - Lymphoblastic Leukemia, Philadelphia-Positive ALL | Not yet recruiting | PETHEMA Foundation | 150 | 2023-12-25 | 2023-12-19 | |
| Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT Imatinib, Ponatinib, Blinatumomab - Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Goethe University | 220 | 2023-07-14 | 2025-04-29 |
| Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients Ponatinib - Chemotherapy, Leukemia, Acute Lymphoblastic | Phase 2 | Active not recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 32 | 2022-10-05 | 2026-03-06 |
| A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia Ponatinib, Venetoclax, Mini-hyper CVD - Acute Lymphoblastic Leukemia, Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2022-06-07 | 2026-04-27 |
| Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL Ponatinib + Blinatumomab, Chemotherapy + Imatinib - Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult | Phase 3 | Active not recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 236 | 2021-09-08 | 2025-01-23 |
| Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse Ponatinib - Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse | Phase 2 | Active not recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 67 | 2021-05-04 | 2024-10-22 |
| Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) Inotuzumab ozogamicin, Dasatinib, Dexamethasone - Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | University of Chicago | 25 | 2021-03-02 | 2026-06-05 |
| A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ponatinib, Chemotherapy Agents - Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL) | Phase 1 / Phase 2 | Terminated | Takeda | 11 | 2021-02-24 | 2025-10-02 |
| Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL Ponatinib 15 MG Oral Tablet - Acute Lymphoblastic Leukemia, Adult, Ph+ ALL | Phase 2 | Terminated | Institute of Hematology and Blood Transfusion, Czech Republic | 4 | 2021-02-16 | 2024-08-14 |
| Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia Ponatinib 15mg QD, Ponatinib 30mg QD - Chronic Myeloid Leukemia (CML) | Phase 2 | Unknown | Associazione Italiana Pazienti Leucemia Mieloide Cronica | 50 | 2021-02-01 | 2021-02-03 |
| Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 348 | 2021-01-25 | 2026-08-28 |
| Study in Adult Ph-positive ALL Ponatinib, Blinatumomab, Imatinib - Acute Lymphoblastic Leukemia, Adult | Phase 2 | Unknown | Cardiff University | 180 | 2021-01-01 | 2020-12-30 |
| Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database Bosutinib, Imatinib, Nilotinib - Chronic Myeloid Leukaemia | Completed | Pfizer | 1484 | 2020-11-18 | 2023-10-27 | |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer | Phase 2 | Unknown | Fondazione per la Medicina Personalizzata | 400 | 2020-10-07 | 2023-10-03 |
Showing 20 of 70. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (26) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (24) · Leukemia (12) · Blast Crisis (7) · Leukemia, Myeloid, Acute (7) · Leukemia, Myeloid, Chronic-Phase (7) · Leukemia, Myeloid, Accelerated Phase (6) · Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Myeloproliferative Disorders (5) · Bone Marrow Diseases (4) · Hematologic Diseases (4) · Leukemia, Myeloid (4) · Neoplasms by Histologic Type (4) · Breast Neoplasms (2)
M.D. Anderson Cancer Center (9) · Ariad Pharmaceuticals (7) · Gruppo Italiano Malattie EMatologiche dell'Adulto (5) · OHSU Knight Cancer Institute (4) · Takeda (3) · Versailles Hospital (3) · Dana-Farber Cancer Institute (2) · National Cancer Institute (NCI) (2) · PETHEMA Foundation (2) · University of Chicago (2) · Antonio Fojo (1) · Assistance Publique - Hôpitaux de Paris (1) · Associazione Italiana Pazienti Leucemia Mieloide Cronica (1) · Cardiff University (1) · Centre Leon Berard (1)
United States (33) · Italy (14) · France (12) · Spain (9) · South Korea (7) · Germany (6) · Australia (5) · China (5) · United Kingdom (5) · Belgium (4) · Canada (4) · Czechia (4) · Netherlands (4) · Poland (4) · Sweden (4)
Elias Jabbour (3) · Andrea Botticelli (1) · Antonio Fojo, MD (1) · Antonio Jimenez, Dr. (1) · Blanca Xicoy, Dr. (1) · Carlo Gambacorti (1) · Carmen Fava (1) · Cyril Salek, MD (1) · Dong-Wook Kim, MD, PhD (1) · Elias Jabbour, MD (1) · Eudocia Lee, MD (1) · Fabian Lang, MD (1) · Farhad Ravandi-Kashani (1)
PMID 41671463, PMID 34699069, PMID 26432046, PMID 36054756, PMID 11756187, PMID 20965785, PMID 22825216, PMID 23190221, PMID 23440689, PMID 23704092, PMID 24166905, PMID 24180494, PMID 24323036, PMID 25763789, PMID 25878120, PMID 26178642, PMID 26291023, PMID 26436130, PMID 26686407, PMID 27083332, PMID 27349810, PMID 27505637, PMID 28218239, PMID 28444644, PMID 28835440, PMID 29567798, PMID 30501869, PMID 30885996, PMID 34407543, PMID 34649276, PMID 34991679, PMID 35091442, PMID 35622074, PMID 35675590, PMID 36402146, PMID 36600670, PMID 38722621, PMID 39028925, PMID 39303729, PMID 39863139, PMID 40025846, PMID 40165400, PMID 40369607, PMID 41023484, PMID 41026957, PMID 41963505, PMID 42174310, PMID 42874102
2018 (4), 2023 (3), 2015 (2), 2014 (1), 2017 (1), 2019 (1), P30CA015083 (1), P30CA069533 (1), R21CA159265 (1), U10CA180820 (1), U10CA180821 (1)